Neuren on track with "watershed" clinical trials
30 January, 2014 by Dylan Bushell-EmblingNeuren (ASX:NEU) is well underway with clinical trials of drug candidate NNZ-2566 in neurological conditions including Fragile X syndrome, Rett syndrome and traumatic brain injury.
Drawbridge wins patents for anaesthesia candidate
30 January, 2014 by Dylan Bushell-EmblingDrawbridge Pharmaceuticals has picked up patents in six countries for Phaxan, its anaesthesia drug candidate that entered the phase IC trial stage this month.
Viralytics to raise up to $27m for cancer trials
30 January, 2014 by Dylan Bushell-EmblingViralytics (ASX:VLA) has launched a capital raising to secure funds for clinical trials of cancer treatment candidate Cavatak in melanoma and other solid tumours.
Access to medical isotopes
30 January, 2014Australian researchers and clinicians can now access locally produced medical isotopes thanks to a new collaborative arrangement.
Nanoparticles provide a new way to treat heart attack
29 January, 2014Researchers are recruiting nanobiology to change the way heart attacks are treated.
Transforming catheter placement
28 January, 2014A new tool that guides catheter placement is being taken up by Australian hospitals.
Starpharma starts human trial of DEP-docetaxel
24 January, 2014 by Dylan Bushell-EmblingStarpharma (ASX:SPL) has received the approvals required to kick off the first human trial of dendrimer-enhanced chemotherapy formulation DEP-docetaxel.
Op-shopping the genome yields RNA gold
22 January, 2014 by Fiona WylieShakespeare’s Hamlet was correct - "what a piece of work is a [hu]man! ... how infinite in faculty" - and now it seems, according to a team of researchers in Sydney, in gene expression regulation.
Patrys's SC1 boosts 10-year survival in gastric cancer
22 January, 2014 by Dylan Bushell-EmblingLong-term follow-up data from a trial of Patrys's (ASX:PAB) IgM antibody PAT-SC1 in gastric cancer shows improved 10-year survival rates in treated patients.
Imugene adds to scientific board
21 January, 2014 by Dylan Bushell-EmblingImugene has appointed to its scientific advisory board two Austrian scientists who were instrumental in the development of the company's cancer vaccine candidate HER-Vaxx.
Abraxane improves survival in pancreatic cancer trial
21 January, 2014 by Dylan Bushell-EmblingAbraxane, a chemotherapy drug licensed in Australia by STA, achieved a three-year overall survival of 4% during a combination trial in metastatic pancreatic cancer.
Prima gets first approval for CAN-004 trial
20 January, 2014 by Dylan Bushell-EmblingBelgium's FAMHP has become the first regulator to sign off on the modified protocol for Prima BioMed's (ASX:PRR) upcoming trial of CVac in ovarian cancer.
New diagnostic test for coeliac disease
20 January, 2014A new blood test that can produce results within 24 hours may provide a simpler and less invasive test for detecting coeliac disease.
Protein blocks escape route for cancer cells
17 January, 2014A protein that can potentially block the spread of cancerous cells is providing new insights into cancer biology.
Patrys raises $1.3m through shortfall issue
17 January, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) has raised $1.3m through a share placement and is working with the managers of last month's rights issue to place more of the shortfall shares.
